Deucravacitinib (Sotyktu) for Plaque Psoriasis
Deucravacitinib (Sotyktu) for Plaque Psoriasis
February 20, 2023 (Issue: 1670)
The FDA has approved deucravacitinib (Sotyktu –
BMS), an oral tyrosine kinase 2 (TYK2) inhibitor, for
once-daily treatment of moderate to severe plaque
psoriasis in adults who are candidates for systemic
therapy or phototherapy....more
- JA Singh et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guidelines for the treatment of psoriatic arthritis. Arthritis Rheumatol 2019; 71:5. doi:10.1002/art.40726
- A Menter et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2020; 82:1445. doi:10.1016/j.jaad.2020.02.044
- Drugs for psoriasis. Med Lett Drugs Ther 2019; 61:89.
- A Chimalakonda et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb) 2021; 11:5. doi:10.1007/s13555-021-00596-8
- AW Armstrong et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 2023; 88:29. doi:10.1016/j.jaad.2022.07.002
- B Strober et al. Deucravacitnib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol 2023; 88:40. doi:10.1016/j.jaad.2022.08.061
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Deucravacitinib (Sotyktu) for Plaque Psoriasis
Article code: 1670b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
